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Abstract: The aim of this study was to investigate the use of botulinum toxin type A (BoNT-A)
injections and their efficacy on gross motor function for lower limb spasticity in children with spastic
cerebral palsy (CP). This retrospective study included 919 injection occasions from 591 children
with CP who received a lower limb BoNT-A injection between 2006 and 2016. The Gross Motor
Function Measure (GMFM-88), the Modified Ashworth Scale, and the Modified Tardieu Scale were
administered before and after injections. Injections were predominantly administered to children
under the age of 6 years. The most common muscle injection site was the calf muscle for dynamic foot
deformity. The second most commonly injected muscle was the hip adductor among 2–3 year olds
and the hamstring muscle among 4–6 year olds. Distal injections were predominantly administered to
high-functioning children, whereas proximal injections were typically administered to low-functioning
children. Multilevel injections were mostly administered to midfunctioning children. GMFM-88
scores significantly increased post-injection for both high- and low-functioning groups. Younger age
at injection and distal injection type were associated with larger improvements on the GMFM-88 at
both short- and midterm follow-up. The target muscles for injection varied depending on gross motor
functioning and age. Younger age at injection and distal injection type were significantly related with
greater gain in gross motor function.
Keywords: cerebral palsy; spasticity; botulinum toxin; motor function
Key Contribution: BoNt-A injections are common under the age of 6. Combined cast application
after injection was more common for children aged over 4 years old. The target muscles for injection
varied depending on gross motor functioning and age. Younger age at injection and distal injection
type were significantly related with greater gain in gross motor function.
1. Introduction
Botulinum toxin type A (BoNT-A) injections are widely used to control lower limb spasticity
in children with spastic cerebral palsy (CP) [1,2]. According to a population-based study, spasticity
of the gastrocnemius muscle, as measured using the Modified Ashworth Scale (MAS), increases in
most children with CP up to the age of 5, followed by a decrease up to the age of 15 [3]. In addition,
a retrospective cohort registry study found that BoNT-A injections for children with CP differed
according to age and level on the Gross Motor Function Classification System (GMFCS) [4].
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During physical development in childhood, the contribution of non-neural components to
hypertonia increases and leads to joint contracture or deformity. As for equinus of the foot, the
increasing muscle stiffness and joint tightness leads to limitation of joint motion (LOM) as the child
grows. Cast applications are known to be useful to improve the passive range of motion (ROM)
at the ankle [5]. Therefore, according to an international consensus statement, cast application is
recommended in combination with BoNT-A injections in the case of LOM at the ankle [6].
Although numerous previous studies have established that BoNT-A injections are effective in
spasticity control and improving ROM [6], its efficacy in functional improvement is less certain [7].
In addition, the contributing factors involved in functional gain are still emerging.
Identification of related factors that allow for the prediction of the effect of BoNT-A injections
could help to guide indications and treatment goals for the injection. Therefore, the aim of the present
study was to investigate whether the efficacy of BoNT-A injections, or a combined case application and
the targeting of different muscles, differed according to age and gross motor function. Additionally,
the study aimed to elucidate whether BoNT-A injections could lead to functional gain and identify
contributing factors relating to functional gain in children with spastic CP.
2. Results
2.1. Demographic Data
In total, 919 injection occasions from 591 participants were analyzed in this study. The sample
included 340 boys and 251 girls, with a mean age at first injection of 4.68 years old (SD 2.22 years, age
range 2–13 years). Among the participants, children classified as ambulatory CP comprised 73.6%
of the sample (GMFCS level I/II/III: 210/111/114), and nonambulatory CP comprised 26.4% (GMFCS
level IV/V: 91/65). Meanwhile, 454 participants (76.9%) had bilateral involvement, and 137 participants
(23.1%) had unilateral involvement. The characteristics of the participants included in this study are
described in Table 1.
Table 1. Participants’ demographic and clinical features.
Characteristic Total 591 Patients
Gender, male 340 (57.5%)
Topography classification
Unilateral 137 (23.2%)
Bilateral 454 (76.8%)
GMFCS level (initial)
I 210 (35.5%)
II 111 (18.8%)
III 114 (19.3%)
IV 91 (15.4%)
V 65 (11.0%)
Age at each injection (years) 4.68 ± 2.22 (2–13)
Values are expressed as mean ± SD (range) or number of participants (percentage); GMFCS, Gross Motor Functional
Classification System.
2.2. Injection Profile
Injections were administered unilaterally on 284 occasions (30.9%) and bilaterally on 635 occasions
(69.1%). Distal injections for foot deformity were given on 502 (54.6%) occasions, while proximal
injections into the muscles of the hip and/or knee joints were administered on 80 (8.7%) occasions.
Multilevel injections targeting the muscles of three joints—the hip, ankle, and/or knee—were given
on 337 (36.7%) occasions (Table 2). The average injection dose of BoTN-A was 9.39 ± 4.82 units. The
injection dose was significantly different depending on the type of injection (p < 0.05).
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Table 2. Injection profile characteristics.
Characteristic 919 Injections/591 Patients
Types of injection
Distal injection only 502 (54.6%)
Proximal injection only 80 (8.7%)
Multi-level injection 337 (36.7%)
Injection dose (unit)
Distal injection only 7.02 ± 3.19
Proximal injection only 9.84 ± 5.11
Multi-level injection 12.88 ± 4.65
Injection site
Unilateral injection 284 (30.9%)
Bilateral injection 635 (69.1%)
GMFM-88 assessment at each time interval
Baseline 919
1st follow-up (within 1–2 months after injection) 825
2nd follow-up (within 3–6 months after injection) 523
Values are expressed as mean ± SD (range) or number of participants (percentage); GMFM, Gross Motor
Function Measure.
The injection type was significantly different according to GMFCS level (Table 3). Participants
with good functioning according to their GMFCS level were more likely to receive a distal, rather than
proximal, injection. The distal injection group predominantly comprised children at a good level of
functioning on the GMFCS, while the proximal injection group mainly encompassed children at a poor
level of functioning on the GMFCS. In the multilevel injection group, the GMFCS level was widely
distributed from GMFCS levels I to V, though participants at the midfunctioning level (GMFCS levels
II to IV) made up the majority of this group (Table 3).
Table 3. Distribution of injection type according to GMFCS level.
GMFCS
Injection Site p-Value
Distal Proximal Multilevel Overall Post-Hoc
I 299 (59.6%) 2 (2.5%) 49 (14.5%)
<0.001 *
Distal vs. proximal <0.001 *
Distal vs. multilevel <0.001 *
Proximal vs. multilevel = 0.329
II 102 (20.3%) 5 (6.3%) 73 (21.7%)
III 46 (9.2%) 18 (22.5%) 100 (29.7%)
IV 33 (6.6%) 20 (25.0%) 79 (23.4%)
V 22 (4.4%) 35 (43.8%) 36 (10.7%)
Values are number of cases (%); Chi-squared test with post hoc Bonferroni correction; GMFCS, Gross Motor
Functional Classification System.
Injections were administered 1–11 times. However, most of the participants for this study received
the injection within 3 times. Injection frequencies of 4 or more occurred on 150 occasions (16.3%;
Table 4).
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Table 4. Distribution of repeat injections.
Group Injection Occasion Injection Frequency Total
I: 1st injection 1st 388 388 (42.2%)
II: 2nd–3rd injection 2nd 248 381 (41.5%)
3rd 133
III: Multiple
injections (≥4 times)
4th 63
150 (16.3%)
5th 40
6th 23
7th 12
8th 6
9th 4
10th 1
11th 1
The most commonly injected muscle in all age groups was the calf muscle to target dynamic foot
deformity. The second most commonly injected muscle was the hip adductor in children aged 2–3 years
and the hamstring muscle in children aged 4–6 years. Injections were predominantly administered to
children under the age of 6 years (Figure 1).
Figure 1. Target muscles according to age group. Calf refers to the gastrocnemius muscle with
or without the soleus, tibialis posterior, or peroneus muscles. Hip adductor refers to the adductor
longus muscle with or without the gracilis muscles. Hamstring refers to the semimembranosus and
semitendinosus muscles.
2.3. Reduction of Tone
Significant improvements on the MAS and R1 (the angle of muscle reaction) on the MTS were
observed for most of the muscles injected at the first and second follow-ups compared to baseline,
but the tone in some of the muscles significantly increased at the second follow-up compared to the
first follow-up (Table 5). As for passive ROM (R2 on the MTS), ankle dorsiflexion, hip abduction, and
popliteal angles had significantly improved at the first follow-up, and these effects were maintained at
the second follow-up.
Toxins 2019, 11, 651 5 of 13
Table 5. Changes in tone in major muscles.
Injection Site Assessed Muscle and Posture
Assessment Time p-Value
Baseline 1st Follow-Up 2nd Follow-Up
Modified Ashworth Scale, median (IQR)
Calf Ankle with knee flexion 2 (1+, 2) 1+ * (1, 1+) 1+ * (1, 2) <0.001 §
Calf Ankle with knee extension 2 (2, 3) 1+ * (1+, 2) 1+ *,† (1+, 2) <0.001 §
Hamstring Knee flexor 2 (1+, 2) 1+ * (1, 1+) 1+ * (1+, 2) <0.001 §
Hip adductor Hip adductor with knee flexion 1+ (1+, 2) 1 * (1, 1+) 1+ *,† (1, 2) <0.001 §
Hip adductor Hip adductor with knee extension 2 (1+, 2) 1+ * (1, 1+) 1+ *,† (1, 2) <0.001 §
Modified Tardieu Scale, R1 (degree)
Calf Ankle with knee flexion −7.79 (15.09) 2.56 * (10.60) −0.04 *,† (13.49) <0.001 §§
Calf Ankle with knee extension −17.88 (14.28) −4.90 * (13.38) −10.80 *,† (13.05) <0.001 §§
Hamstring Knee flexor 67.24 (17.11) 49.22 * (16.18) 59.69 *,† (21.25) <0.001 §§
Hip adductor Hip adductor with knee flexion 35.71 (13.84) 48.80 * (12.90) 43.08 * (14.98) <0.001 §§
Hip adductor Hip adductor with knee extension 16.93 (7.85) 28.75 * (8.33) 23.72 *,† (10.62) <0.001 §§
Modified Tardieu Scale, R2 (degree)
Calf Ankle with knee flexion 17.14 (12.73) 23.36 * (11.33) 21.93 * (11.50) <0.001 §§
Calf Ankle with knee extension 7.05 (11.72) 13.32 * (10.73) 11.34 * (10.77) <0.001 §§
Hamstring Knee flexor 38.49 (15.65) 29.79 * (12.92) 36.35 * (16.04) <0.001 §§
Hip adductor Hip adductor with knee flexion 57.95 (12.13) 63.21 * (10.48) 61.63 (13.93) 0.001 §§
Hip adductor Hip adductor with knee extension 30.96 (10.19) 38.56 * (7.26) 34.63 * (9.63) <0.001 §§
Values are expressed as median (IQR) or mean (SD); 1st follow-up, within 1–2 months after injection; 2nd follow-up, within 3–26 months after injection; § p < 0.05, generalized estimating
equations (GEE) model, §§ p < 0.05, linear-mixed model; * post hoc analysis, compared with baseline, p < 0.05; † post hoc analysis, compared with 1st follow-up data, p < 0.05.
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2.4. Combined Short Leg Cast Application
The frequency of cast application after injection was significantly different according to age group.
The frequency of cast application was significantly higher in children aged over 4 years old compared
to children aged 2–3 years (Table 6).
Table 6. Distribution of children treated with casts in different age groups.
Serial Cast
Age Group at Each Injection p-Value
I: 2–3 Years II: 4–6 Years III: 7–9 Years IV: >10 Years Overall Post-Hoc
Cast/Total 50/403(12.4%)
83/393
(21.1%)
31/92
(33.7%)
12/31
(38.7%) <0.001 *
I vs. II = 0.006 *
I vs. III < 0.001 *
I vs. IV < 0.001 *
II vs. III = 0.084
II vs. IV = 0.246
III vs. IV > 0.999
* p < 0.05, Chi-square test with post-hoc Bonferroni correction.
2.5. GMFM-88 Change
Both ambulatory and nonambulatory groups demonstrated significant gains on the Gross Motor
Function Measure (GMFM-88) at both short and midterm follow-ups compared to baseline assessment,
but only ambulatory children had significantly improved on the GMFM-88 at the second follow-up
assessment (within 3−6 months) compared to the first follow-up assessment (within 1−2 months)
(Table 7).
Table 7. Changes in GMFM-88 score after injection.
GMFM-88 p-Value
Baseline 1st Follow-Up 2nd Follow-Up
Functional level
Ambulatory (GMFCS I-III) 76.57 (20.83) 78.77 (19.47) * 80.96 (18.70) *,† <0.001§
Non-ambulatory (GMFCS IV-V) 30.27 (20.98) 32.00 (21.71) * 34.32 (19.78) * <0.001§
Injection occasion
1st injection 59.55 (30.30) 61.38 (29.97) * 64.95 (28.37) *,† <0.001§
2nd-3rd injection 67.52 (27.54) 70.84 (27.96) * 70.37 (27.96) *,† <0.001§
4th or more injection 74.17 (25.30) 76.20 (23.78) * 75.48 (25.27) * 0.005 §
Values are expressed as mean (SD); 1st follow-up, within 1–2 months after injection; 2nd follow-up, within 3–6
months after injection; § p < 0.05, linear-mixed model; * post hoc analysis, compared with baseline, p < 0.05; † post
hoc analysis, compared with 1st FU data, p < 0.05.
In addition, the present study revealed a significant improvement in GMFM-88 scores following
multiple injections, but this improvement was significantly smaller compared to children who had
received either one or two-to-three injections (Figure 2).
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Figure 2. Changes in gross motor function according to multiple injection groups. Group I, first
injection; Group II, second or third injection; Group III: multiple injections (≥4 times). * p < 0.05 using
ANOVA with post hoc Bonferroni correction.
2.6. Factor Analysis of Changes in GMFM-88 Scores
A univariate analysis of both short-term and midterm changes revealed that age at injection,
injection type, and number of repeat injections were significant factors associated with gains on the
GMFM-88. A multivariate analysis revealed that the age at injection and injection type continued to be
significant factors associated with changes on the GMFM-88 at short- and midterm follow-up (Table 8).
Table 8. Linear regression analysis of factors associated with GMFM-88 total change.
At Primary End-Point
(1–2 Months after Injection)
At Follow-Up
(3–6 Months after Injection)
Univariate Multivariate Univariate Multivariate
Variable B (SE) B (SE) B (SE) B (SE)
Age at injection −0.30 * (0.07) −0.23 * (0.07) −0.63 * (0.13) −0.51 * (0.15)
GMFCS
- -Level I-III ref ref
Level IV-V −0.42 (0.34) −0.86 (0.69)
Body involvement
- -Unilateral ref ref
Bilateral 0.61 (0.36) 0.97 (0.18)
Injection type
Distal only ref ref ref ref
Proximal only −1.46 * (0.54) −1.31 * (0.54) −3.08 * (1.10) −2.75 * (1.07)
Multilevel 0.73 * (0.31) 0.60 (0.31) 0.41 (0.64) 0.11 (0.63)
Injection Occasion
1st injection ref ref ref ref
2nd, 3rd injection −0.35 (0.32) −0.23 (0.32) −1.46 * (0.66) −0.99 (0.66)
≥4th injection −1.16 * (0.45) −6.51 (0.47) −2.48 * (0.88) −1.22 (0.93)
* p < 0.05 using linear regression analysis. SE, standard error; GMFCS, Gross Motor Functional Classification System;
ref, reference group.
3. Discussion
According to a previous population-based study, BoNT-A injections were predominantly
administered to the calf muscle in ambulatory children (GMFCS level I to III) and to the hamstring and
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adductor muscles in nonambulatory children (GMFCS level IV to V) [4]. The literature indicates that
multilevel injections were most commonly given to children at levels II to IV on the GMFCS, even
though it could also be administered to children at levels I or V [8–12]. The results of our study are
in line with these observations. Focal spasticity, such as equinus gait, is a more common issue than
diffuse spasticity in children with good gross motor functioning. On the other hand, proximal muscle
injections were commonly administered to children at level V on the GMFCS because of their high risk
of hip dislocation or subluxation. Meanwhile, multilevel injections were typically given to children at
levels II to IV on the GMFCS. These findings suggest that the target muscles for injection can differ
depending on the level of gross motor functioning.
BoNT-A injections are known to be an effective intervention for dynamic spasticity but not static
contracture. Therefore, children with spastic CP usually received the BoNT-A injection before the
development of static contracture, which is often the target for orthopedic surgery. In a previous
population-based study, BoNT-A injections were most frequently administered to children aged
4–6 years [4]. The results of the present study are in line with these previous findings.
Equinus foot is the most common deformity in children with CP. A retrospective cohort registry
study demonstrated that the gastrocnemius muscle was the most common muscle treated with BoNT-A
injections irrespective of age or level of gross motor function [4]. In addition, the hip adductor muscle
was the second most commonly targeted muscle among children under 4 years old, whereas the
hamstring muscle was the second most commonly targeted muscle for BoNT-A injections among
children over the age of 4, and reached a peak in children aged 10–12. The results of our study
demonstrated a similar pattern. The degree of spasticity often decreases between 4–5 years and
12–15 years of age [3,13]. The combination of reduced muscle tone, increased body weight with age,
and reduced muscle strength might contribute to the development of crouch gait. As such, hamstring
muscle injections seem to be increasingly administered to older children. Compared to an earlier study
conducted by Franzen et al. [4], the present study revealed an earlier peak, at the age of 4–6 years, for
hamstring injections. This might be due to the fact that orthopedic intervention for the correction of
musculoskeletal malalignment, such as joint contracture and dislocation, is commonly implemented
from the age of seven at our institute. Taken together, these findings suggest that the use of BoNT-A
injections as a therapeutic intervention, and the muscle group targeted varied depending on age.
Combined therapy—using a serial or single short leg cast with BoNT-A injections—is thought
to achieve optimal improvements for equinus [14]. In our clinic, a cast was applied for participants
with ankle joint LOM if there was no longstanding contracture. In children with spastic CP, the
neural factor—increased muscle activity caused by velocity-dependent pathological stretch reflex by
definition—is the main reason for increased resistance to passive joint motion. As a child grows, the
non-neural mechanical properties of soft tissue and joint structures, such as stiffness and viscosity,
can increasingly contribute to increased resistance to passive stretch. In a previous study, the range
of dorsiflexion of the ankle joint decreased as the child grew to 18 years of age, while the annual
decrease was fastest up to approximately 5–6 years of age [15]. Because of the increased contribution of
non-neural factors for equinus foot as the child grows, cast application after injection was significantly
more common in children aged over four years, compared to younger children.
In previous studies, BoNT-A injections, or combined therapy with BoNT-A and physiotherapy, led
to greater improvements on the GMFM-88 in children with CP than physiotherapy [8,16–19], although
one report found conflicting evidence [20]. In addition, injection technique [21], gross motor function,
and age [4,22] were suggested as factors associated with changes on the GMFM-88 [23].
Using BoNT-A injections as an intervention has a long-term effect on motor function, even though
the effect of the injection on muscle tone had disappeared [9,24–26]. The degree of improvement in
gross motor function with intensive physical therapy and repeated BoNT-A injections might be greater
at long-term follow-up as the child develops and grows. In this context, a long-term follow-up study
could lead to a greater gain in gross motor function after injection in combination with intensive
physical therapy [8]. Therefore, the baseline was set as the GMFM-88 score before the last BoNT
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injection, but not the first injection, to minimize the influence of child development. In the present study,
participants demonstrated some improvement on the GMFM-88 when they received four or more
repeated injections, though the degree of improvement was smaller compared to the improvements
seen after the first, and second or third injections. These findings are in line with the results of previous
studies [24,27], in which the efficacy of BoNT-A apparently declined with repeated injections, with
most children benefitting from two to three injections. Scores on the GMFM-88 reached a plateau
between ages three and seven depending on their GMFCS level [28], and thus age has been reported
as a significant factor associated with gains on the GMFM-88 after BoNT-A injection in previous
studies [22,29] as well as the present study.
The efficacy of BoNT-A injections has been proven in the treatment of spastic equinus in ambulant
children with CP (GMFCS levels I to III) with the aim of improving gait pattern [30,31]. There are
some positive reports showing gains on the GMFM-88 after administering injections to children with
CP [8,9,22,24]. However, the question of whether BoNT-A injections in combination with physical
therapy facilitates greater improvements in gross motor function is inconclusive because of the poor
level of existing evidence, according to systematic reviews [23,32].
The effect of gross motor functioning in relation to functional gain, as measured by the GMFM-88,
has rarely been reported. In a previous study, moderately impaired children (GMFCS level III) showed
a tendency to attain higher gains in GMFM-88 scores, but these improvements were not statistically
significant [22]. Another report showed that children with moderate functional impairment (GMFCS
levels III to IV) demonstrated higher gains on the GMFM-88, but only one in five children at GMFCS
level V showed improvements on the GMFM-88 [33]. In general, the use of BoNT-A injections
in children with severe functional impairment is usually aimed at reducing pain, preventing hip
dislocation, and improving ease in care and positioning [32]. Our study demonstrated significant gains
in nonambulatory children. The efficacy of BoNT-A injections in terms of functional change on the
GMFM-88 according to GMFCS level requires further investigation. Furthermore, it is of interest that
injection type, not ambulatory function, was a factor associated with gains on the GMFM-88 in the
present study. We observed that injection type differed based on the level of gross motor functioning on
the GMFCS. The main purpose of BoNT-A injections for children at GMFCS level V was the prevention
of hip subluxation and to ease care, thus proximal injections were predominantly performed. As such,
injection type was significantly associated with changes on the GMFCS in the present study. To the
best of our knowledge, there have been no reports examining functional gains according to injection
type. Further studies of rigorous methodological quality are required.
This was a retrospective study in a single center, though most of the included children with CP
visited our clinic especially for BoNT-A injections. We established the protocol for children with CP
who had received BoNT-A injections for the assessment, but some children were missed during the
courses. However, this did not appear to significantly impact our results. In addition, the amount of
physical therapy received after injection varied to some extent, but we did not expect the outcome to be
significantly affected. As the importance of intensive physical therapy after injection was emphasized
to the parents of children who had received BoNT-A injections, physical therapy was performed on
most of the children. Regardless of these limitations, a strength of this study is that GMFM-88 changes
could be assessed in a relatively large number of cases, enabling us to delineate factors associated with
changes on the GMFM-88 after injection.
4. Conclusions
Our study revealed that BoNT-A injections are common under the age of six, and combined
cast application after injection for equinus foot became increasingly more common from the age of
four. The target muscles for injection varied depending on the level of gross motor function and age.
The gross motor functional changes, as measured with the GMFM-88, were significantly associated
with age at injection as well as injection type in children with spastic CP.
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5. Materials and Methods
5.1. Study Design
This study was conducted in a pediatric spasticity management clinic in a university-affiliated,
tertiary-care teaching hospital. In this clinic, children with CP were regularly followed by a multidisciplinary
clinic team of three pediatric physiatrists, nurses, physiotherapists, and an occupational therapist.
For this study, the medical records of children with spastic CP who had received BoNT-A injections,
with or without neurolysis or motor point block, with ethyl alcohol in the lower limb between January
2006 and December 2016 were retrospectively reviewed. The medical records of 2329 injection occasions
of 1213 children were reviewed. Of these records, children under 13 with full assessments before
injection and a follow up assessment at least once after injection were selected for this study. As a
result, the data from a total of 919 injections from 591 children with CP were analyzed.
This study was approved by the Institutional Review Board of the Severance Hospital (4-2019-0587).
Informed consent for BoNT-A injection was obtained from the parents of all children in this study.
In addition, oral or written assent was also obtained from the children over 7 years old according to
their understanding and cognitive abilities.
5.2. Intervention
At our clinic, children with spastic CP are regularly followed in order to provide appropriate
interventions, including BoNT-A injections, in a timely manner. At every visit, spasticity, ROM, gross
motor skills, and movement or gait patterns are assessed. In the case of patients receiving BoNT-A
injections, the selection of muscles and the dosage to be injected was determined by the physician
based on clinical assessments including the MAS, MTS, the Hypertonia Assessment Tool (HAT) if
possible, and the GMFM-88. One vial containing 100 units of onabotulinum toxin-A (Botox®, Allergan
Inc, Irvine, CA, USA) was diluted with 2 mL normal saline; 200 units of Neu-BoNT/A (Neuronox®,
Medytox Inc, Ochang-eup, Cheongwon-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea)
was diluted with 4 mL normal saline. For the children who received multilevel injections, nerve
block with 50% ethyl alcohol was added if the total dose per one session exceeded the maximal safe
dosage (a total of 16–20 U/kg of body weight depending on general health status, such as respiratory
health or malnutrition, etc.). Obturator nerve block, tibial nerve block to the gastrocnemius muscle,
or motor point block to the hamstring muscle was administered depending on whether additional
nerve or motor point block was needed. Depending on the size and the severity of spasticity of
the target muscles, 1–5 U/kg botulinum toxin was injected per muscle. The total muscle dose was
divided between two to four injection sites depending on muscle size. Injections were guided by
ultrasonography or by electrical stimulation for the exact identification of target muscles or nerve or
motor point blocks. Electrical stimulation for nerve or motor point blocks was administered under
general anesthesia. Distal injections were defined as those that were confined to the calf muscle
when used to treat a foot deformity, such as equinus with or without varus or valgus foot. For distal
injections, the gastrocnemius muscle was the main target muscle on all occasions. Meanwhile, the
peroneus muscle or tibialis posterior muscle were also injected on nine occasions when equinus was
accompanied by varus or valgus foot. In some hemiplegic children with equinus foot, both the soleus
muscle and the gastrocnemius muscle were injected. Proximal injections were defined as those that
were confined to the hip muscles, such as the hip adductor or iliopsoas muscle, and/or the hamstring
muscle, without the calf muscle injection for foot deformity. Most of the children who had proximal
injections had received the injection into both the hip adductor and/or hamstring muscles. Multilevel
injections were defined as those that were distributed diffusely from hip to ankle joint muscles. For
multilevel injections, the gastrocnemius, hamstring, hip adductor, iliopsoas, and rectus femoris were
the target muscles based on the clinical assessment.
For children who had LOM at the ankle joint, a short leg cast was applied for one to three weeks
(depending on the degree of LOM) to increase the ROM after injection. The short leg casts were applied
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with the patient in a prone position with the knee flexed to 90◦ and the ankle dorsiflexed to maximal
attainable dorsiflexion and held in the neutral hind foot position. The consecutive cast was applied
with a progressively increasing degree of ankle dorsiflexion to stretch the calf. The importance of
intensive physical therapy after injection was emphasized to all parents. Subsequently, most of the
children in the study received intensive physical therapy.
5.3. Assessment
Using the GMFM-88, a physical therapist assessed the gross motor function of children who
received a BoNT-A injection in the lower limb. The physiatrist assessed muscle tone using the MAS
and MTS by assessing the ROM in each joint and by determining the child’s GMFCS level. All children
who received the injection were assessed before and after the injection was administered. Follow-up
assessments were conducted 1–2 months post-injection, and again 3–6 months post-injection.
The level of gross motor functioning of children with CP can be classified according to the GMFCS,
which consists of five levels, from level I (most able) to level V (least able). The GMFCS is the most
widely used system to classify gross motor function in children with CP. The GMFCS levels used for
this study were determined based on classification at the last visit. High functioning was defined as
ambulatory children at GMFCS level I to III, while low functioning was defined as nonambulatory
children at GMFCS levels IV to V.
Functional gross motor gains were assessed by physical therapists using the GMFM-88. Evidence
indicates that the GMFM-88 is a valid and reliable measurement tool [34]. The short-term follow-up
assessment was conducted between 1–2 months after injection, whereas the midterm follow-up
assessment was conducted between 3–6 months after injection. For children who received multiple
injections, the baseline assessment before the last injection was chosen for measuring the changes.
5.4. Statistical Analyses
Statistical analysis was performed using the Statistical Package for the Social Sciences for Windows
(SPSS version 20.0, IBM SPSS Incorporated, Chicago, IL, USA). Chi-squared tests were used to compare
the distribution of injection types according to GMFCS level. Linear mixed or generalized estimating
equation models were used to analyze the changes in GMFM-88 score, MTS angle, and MAS grade
after intervention in each group. Post hoc Bonferroni correction was used for multiple comparisons.
The independent t test was used to compare the differences in improvement between the groups.
Additionally, univariate and multivariate linear regression modeling were used to identify factors
significantly associated with functional change after injection. A p-value less than 0.05 was considered
statistically significant for all statistical tests.
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